維生素概念板塊持續走強 新和成(002001.SZ)漲超4%
格隆匯11月18日丨維生素概念板塊持續走強,新和成漲超4%,浙江醫藥漲近4%,兄弟科技、聖達生物等緊隨其後。

消息上,目前生豬行業正加緊恢復產能,飼料需求明顯加大。生物素是維生素大家族中一員,主要用於飼料添加劑,業內消息稱目前維生素市場供給較為緊張。
近日,接受採訪的生物素供需雙方,不約而同喊“缺貨”。科興化工相關負責人稱,生物素市場的供給緊張的狀態,在短期內不太可能會改變,提價是大概率事件。
作為生物素生產大國兼出口大國,我國生物素行業的分佈較為集中,主要生產廠家主要包括,聖達生物、新和成、浙江醫藥、海嘉諾醫藥和科興生物,五大生產企業的市場份額合計達90%以上。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.